APAC IVD companies to watch in the infectious diseases diagnostics market

Covid-19: point-of-care vs. lab-based testing


Covid-19 testing has emerged as a top priority for clinical laboratories and many IVD players. SARS-CoV-2 tests make up more than half of Asia-Pacific’s (APAC’s) total infectious disease diagnostics market. 

The use of different tests across APAC varies according to each country’s covid-19 strategy and local testing capacity.

  • Molecular diagnostics (MDx): molecular testing is the predominant test method in APAC. MDx tests make up more than 85% of total covid-19 test volume in Singapore which has strong laboratory-based molecular testing capacity. 
  • Immunoassays: Indonesia conducts a comparatively higher proportion of covid-19 testing using immunoassays. Mass testing in the country relied heavily on serological tests. In 2020, Indonesia’s immunoassay test volume per capita was three times as much as in China.
  • Point-of-care (POC) diagnostics: India and Indonesia have a comparatively higher utilisation of POC diagnostics for covid-19 testing. In 2020, India’s POC test volume amounted to almost similar levels for laboratory-based testing—which include immunoassays and MDx tests carried out at central and molecular labs.

For more on the infectious diseases testing market, download the briefing paper on Infectious disease diagnostics in Asia-Pacific

Track Infectious Disease Diagnostics Market Size, Share and Trends

Access interactive data on infectious disease testing in 16 APAC countries